scholarly journals Prophylactic antibiotic treatment with TMP-SMX decreased the incidence of interstitial pneumonia in patients with B-cell lymphoma on chemotherapy

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Cong Li ◽  
Fangxiao Lu ◽  
Tao Lei ◽  
Haifeng Yu ◽  
Xi Chen ◽  
...  
Keyword(s):  
B Cell ◽  
Interstitial Pneumonia ◽  
Antibiotic Treatment ◽  
Cell Lymphoma ◽  
Prophylactic Antibiotic ◽  
B Cell Lymphoma ◽  
Prophylactic Antibiotic Treatment

Lymphocytic infiltrations of the lung

2020 ◽  
pp. 4241-4244
Author(s):  
S. J. Bourke
Keyword(s):  
Connective Tissue ◽  
B Cell ◽  
Interstitial Pneumonia ◽  
Lymphoid Tissue ◽  
Poor Prognosis ◽  
Cell Lymphoma ◽  
Connective Tissue Diseases ◽  
B Cell Lymphoma ◽  
Low Grade ◽  
High Grade

Lymphocytic infiltrations of the lung arise from the proliferation of bronchus-associated lymphoid tissue, resulting in a spectrum of rare conditions ranging from benign polyclonal lymphoid interstitial pneumonia to monoclonal primary malignant lymphomas of the lung. Lymphoid interstitial pneumonia is most commonly seen in Sjögren’s syndrome or other connective tissue diseases, and in association with HIV infection, and is characterized by reticulonodular shadowing on CT imaging and (usually) a good response to corticosteroids. Primary pulmonary lymphomas fall into three categories: lymphomatoid granulomatosis, low-grade B-cell lymphoma, and high-grade B-cell lymphoma. The latter require treatment with cytotoxic drugs and have a poor prognosis.

Multilesional Primary Cutaneous Diffuse Large B-Cell Lymphoma Responsive to Antibiotic Treatment

Dermatology ◽  
2001 ◽  
Vol 203 (2) ◽  
pp. 168-170 ◽  
Author(s):  
Günther F.L. Hofbauer ◽  
Birgit Kessler ◽  
Werner Kempf ◽  
Frank O. Nestle ◽  
Günter Burg ◽  
...  
Keyword(s):  
B Cell ◽  
Antibiotic Treatment ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Prophylactic antibiotic treatment with TMP-SMX decreased the incidence of interstitial pneumonia in patients with B-cell lymphoma on chemotherapy

2020 ◽  
Author(s):  
Cong Li ◽  
Fangxiao Lu ◽  
Lei Tao ◽  
Haifeng Yu ◽  
Xi Chen ◽  
...  
Keyword(s):  
Risk Factors ◽  
B Cell ◽  
Interstitial Pneumonia ◽  
Prophylactic Treatment ◽  
Significant Risk ◽  
Prophylactic Antibiotic ◽  
B Cell Lymphoma ◽  
Once Daily ◽  
Non Hodgkin Lymphoma ◽  
Associated Risk Factors

Abstract Background Several studies have reported the incidence of interstitial pneumonia (IP) among patients with non-Hodgkin lymphoma (NHL) that are undergoing combination chemotherapy plus rituximab; however, the effective prophylactic treatment for IP remains unclear. This study aims to explore the prophylactic effect of trimethoprim-sulfamethoxazole (TMP-SMX) on IP and identify IP-associated risk factors in NHL patients.Methods Between March 2013 and April 2018, 498 patients (264 males, 53%) with B-cell NHL undergoing first-line RCHOP-like chemotherapy treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone were enrolled in this study.Results These patients had a median age of 56 years, and 311 of the 498 patients (62.4%) were administered once daily with the prophylactic treatment of TMP-SMX. IP occurred in 65 patients (13.1%), indicating a significant reduction in the IP incidence rate (21.4% vs. 8.0%; p<0.001). Among patients treated with TMP-SMX, 2 (1.2%) exhibited rashes, 38 (12.2%) suffered from nausea and vomiting, 52 (16.7%) showed signs of neutropenia, and 18 (5.8%) suffered from kidney dysfunction. Both univariate and multivariate analysis showed that gender (male), history of diabetes, and absence of prophylactic TMP-SMX treatment were significant risk factors associated with IP. Disease progression was observed in 55/311 (17.7%) patients that underwent prophylactic TMP-SMX treatment and in 63/187 (33.7%) patients that did not (p<0.001).Conclusions This study revealed that the occurrence of IP was common in B-cell NHL patients undergoing combined chemotherapy plus rituximab treatment. IP could be reduced with prophylactic treatment of once-daily oral TMP-SMX.

scholarly journals A Case of Intravascular Diffuse Large B-Cell Lymphoma Initially Suspected as Interstitial Pneumonia Associated With Systemic Scleroderma

2021 ◽  
Vol 9 ◽  
pp. 232470962199922
Author(s):  
Tomoyo Oguri ◽  
Shinji Sasada ◽  
Yuki Aramaki-Sumii ◽  
Yumi Tsuchiya ◽  
Kota Ishioka ◽  
...  
Keyword(s):  
B Cell ◽  
Interstitial Pneumonia ◽  
Cell Lymphoma ◽  
Ground Glass Opacity ◽  
B Cell Lymphoma ◽  
Systemic Scleroderma ◽  
Ground Glass ◽  
Serum Lactate Dehydrogenase ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Intravascular large B-cell lymphoma (IVLBCL) is a rare form of diffuse LBCL. The patient was a 71-year-old female admitted to our hospital with hypoxia. On admission, chest computed tomography revealed a ground-glass opacity. Interstitial pneumonia associated with systemic scleroderma was suspected because of positive anti-centromere antibody. Thereafter, steroid pulse therapy and plasma exchange were performed. Although ground-glass opacity improved, bilateral pleural effusion appeared, so we performed a random skin biopsy because of her elevated serum lactate dehydrogenase and soluble interleukin-2 receptor levels. The patient was diagnosed with IVLBCL with symptoms improving after 6 cycles of rituximab plus chemotherapy treatment.

Low Absolute Lymphocyte Count and Addition of Rituximab Confer High Risk for Interstitial Pneumonia In Patients with Diffuse Large B Cell Lymphoma

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 1805-1805
Author(s):  
Yuan-Bin Yu ◽  
Yu-Chung Huang ◽  
Chia-Jen Liu ◽  
Jih-tung Pai ◽  
Hsueh-Ju Lu ◽  
...  
Keyword(s):  
Risk Factors ◽  
B Cell ◽  
Interstitial Pneumonia ◽  
Lymphocyte Count ◽  
Conflicts Of Interest ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Absolute Lymphocyte Count ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Abstract Abstract 1805 Purpose: Several studies reported pulmonary toxicities in patients with diffuse large B cell lymphoma (DLBCL) receiving rituximab and chemotherapy. This retrospective study aimed to determine the risk factors and clinical characteristics of interstitial pneumonia in patients with DLBCL. Methods: From January 2000 to May 2009, 529 consecutive patients with DLBCL receiving first-line COP- or CHOP-based chemotherapy with or without rituximab in Taipei Veterans General Hospital were enrolled. Interstitial pneumonia (IP) was defined as diffuse pulmonary interstitial infiltrates found on computed tomography scan as well as respiratory symptoms. Patient characteristics and outcome parameters were retrieved via medical chart review. Results: IP was observed in 26 patients (4.9%) and 6 of them were confirmed asPneumocystis jirovecii pneumonia. The median number of chemotherapy course to IP was 4 cycles (range, 1–7). By multivariate logistic regression, absolute lymphocyte count (ALC) less than 1×109/L before treatment (odds ratio [OR] 2.75, 95% confidence interval [CI] 1.23–6.19) and addition of rituximab to chemotherapy (OR 4.56, 95% CI 1.68–12.39) were identified as independent risk factors for IP. In the rituximab-treated patients, low ALC at baseline further increased the risk for IP. Conclusions: Incidence of IP is increased in patients with DLBCL receiving rituximab-containing chemotherapy. Specific subgroup with lymphopenia at diagnosis should receive more attention in detecting this pulmonary complication. Disclosures: No relevant conflicts of interest to declare.

Diffuse Large B-cell Lymphoma of the Lung in a Patient With Nonspecific Interstitial Pneumonia

2019 ◽  
Vol 15 (6) ◽  
pp. e151-e152
Author(s):  
Luis Gorospe Sarasúa ◽  
Paola Arrieta ◽  
Anabelle Chinea-Rodríguez ◽  
Carlos de la Puente-Bujidos
Keyword(s):  
B Cell ◽  
Interstitial Pneumonia ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Nonspecific Interstitial Pneumonia ◽  
Large B Cell

scholarly journals Prophylactic antibiotic treatment with TMP-SMX decreased the incidence of interstitial pneumonia in patients with B-cell lymphoma on chemotherapy

2020 ◽  
Author(s):  
Cong Li ◽  
Fangxiao Lu ◽  
Lei Tao ◽  
Haifeng Yu ◽  
Xi Chen ◽  
...  
Keyword(s):  
Risk Factors ◽  
B Cell ◽  
Interstitial Pneumonia ◽  
Prophylactic Treatment ◽  
Significant Risk ◽  
Prophylactic Antibiotic ◽  
B Cell Lymphoma ◽  
Once Daily ◽  
Non Hodgkin Lymphoma ◽  
Associated Risk Factors

Abstract Background Several studies have reported the incidence of interstitial pneumonia (IP) among patients with non-Hodgkin lymphoma (NHL) that are undergoing combination chemotherapy plus rituximab; however, the effective prophylactic treatment for IP remains unclear. This study aims to explore the prophylactic effect of trimethoprim-sulfamethoxazole (TMP-SMX) on IP and identify IP-associated risk factors in NHL patients.Methods Between March 2013 and April 2018, 498 patients (264 males, 53%) with B-cell NHL undergoing first-line RCHOP-like chemotherapy treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone were enrolled in this study.Results These patients had a median age of 56 years, and 311 of the 498 patients (62.4%) were administered once daily with the prophylactic treatment of TMP-SMX. IP occurred in 65 patients (13.1%), indicating a significant reduction in the IP incidence rate (21.4% vs. 8.0%; p<0.001). Among patients treated with TMP-SMX, 2 (1.2%) exhibited rashes, 38 (12.2%) suffered from nausea and vomiting, 52 (16.7%) showed signs of neutropenia, and 18 (5.8%) suffered from kidney dysfunction. Both univariate and multivariate analysis showed that gender (male), history of diabetes, and absence of prophylactic TMP-SMX treatment were significant risk factors associated with IP. Disease progression was observed in 55/311 (17.7%) patients that underwent prophylactic TMP-SMX treatment and in 63/187 (33.7%) patients that did not (p<0.001).Conclusions This study revealed that the occurrence of IP was common in B-cell NHL patients undergoing combined chemotherapy plus rituximab treatment. IP could be reduced with prophylactic treatment of once-daily oral TMP-SMX.

Sign in / Sign up

Export Citation Format

Share Document